PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Weight gain

Drugs in development · updated 30 October 2026

Weight gain: drugs in development

As of 30 October 2026 there are 5 active clinical trials (recruiting or ongoing, phases I–III) on 10 drugs for weight gain. 0 are experimental, that is not yet approved in the United States.

5Active trials
0Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
DapagliflozinForxiga, Dapagliflozin PropanediolIII1NCT06317051
DelstrigoIII1NCT05924438
EzetimibeEzetemibe, Zetia®III1NCT06317051
PitavastatinNikita®, Zypitamag®III1NCT06317051
RosuvastatinEzallor Sprinkle®, Crestor®III1NCT06317051
TirzepatideZepbound, MounjaroIII1NCT06439277
DolutegravirTivicay Pd®, Tivicay®II1NCT05652478
MetreleptinMyalept®, Myalepta®II1NCT06305182
Tenofovir alafenamideVemlidy®II1NCT05652478
Tenofovir Disoproxil FumarateTenofovir, Viread®II1NCT05652478

Sorted by most advanced phase and number of active trials.

All 10 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D015430 “Weight Gain”.

ItalianoFrançaisDeutsch